NAMPT Inhibitors Market is segmented By Application (Oncology, Hematology), By Mechanism of Action (NAMPT Inhibition, NAD+ Modulation), By Geography (....
Market Size in USD
CAGR12.5%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 12.5% |
Market Concentration | Medium |
Major Players | Pfizer Inc., Novartis AG, Johnson & Johnson, Merck & Co., Inc., AbbVie Inc. |
The NAMPT inhibitors market is estimated to be valued at USD 1.5 Bn in 2024 and is expected to reach USD 3.5 Bn by 2031, growing at a compound annual growth rate (CAGR) of 12.5% from 2024 to 2031. The growing prevalence of diseases like cancer and inflammatory conditions is expected to drive the demand for NAMPT inhibitors during the forecast period. These drugs have shown promising results in lowering inflammation and inducing cell death in tumor cells during clinical trials.
The NAMPT inhibitors market is expected to witness high growth owing to rising investments in developing novel and targeted therapies. Major pharmaceutical companies have started developing more potent and selective NAMPT inhibitors to tap into the potential opportunities. Furthermore, the successful completion of late stage clinical trials and regulatory approvals of candidates will further aid the market size expansion in the coming years.